Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1996-2-20
|
pubmed:abstractText |
Vastus lateralis muscle samples were obtained by needle biopsy from 18 healthy elderly men (65-82 yr) participating in a double blind, placebo (PL)-controlled trial of recombinant human GH (rhGH) and exercise and assessed for muscle morphology and skeletal muscle tissue expression of GH and insulin-like growth factors (IGFs). Subjects initially underwent progressive resistance training for 14 weeks and were then randomized to receive either rhGH (0.02 mg/kg BW.day, sc) or PL while undertaking a further 10 weeks of training. Muscle samples were obtained at baseline and at 14 and 24 weeks. The mean (+/- SEM) cross-sectional areas of type I and II fibers were similar (type I, 3891 +/- 167 microns2; type II, 3985 +/- 200 microns2) at baseline and increased (P < 0.01) by 16.2 +/- 4.1% and 11.8 +/- 3.8%, respectively, after the initial 14-week training period. After treatment (weeks 14-24), two-way repeated measures ANOVA revealed a main effect of time for type I (P < 0.01) and type II fibers (P < 0.05), but no group effect or interaction. The increase in cross-sectional area for the PL group was significant (P = 0.01) for type I (11.5 +/- 3.6%) and approached significance (P = 0.06) for type II fibers (11.1 +/- 5.6%). For rhGH, the change in type I (6.3 +/- 5.9%) and II (7.1 +/- 5.2%) fiber area was not significant. No apparent change in tissue GH receptor, IGF-I, IGF-I receptor, IGF-II, or IGF-II receptor messenger ribonucleic acids occurred as a result of exercise after the 14-week pretreatment period or after treatment with rhGH or PL. These results indicate that rhGH administration in exercising elderly men does not augment muscle fiber hypertrophy or tissue GH-IGF expression and suggests that deficits in the GH-IGF-I axis with aging do not inhibit the skeletal muscle tissue response to training.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Growth Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Somatomedin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Somatotropin,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Somatomedins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0021-972X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
81
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
421-5
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8550787-Aged,
pubmed-meshheading:8550787-Aged, 80 and over,
pubmed-meshheading:8550787-Base Sequence,
pubmed-meshheading:8550787-Double-Blind Method,
pubmed-meshheading:8550787-Gene Expression,
pubmed-meshheading:8550787-Growth Hormone,
pubmed-meshheading:8550787-Humans,
pubmed-meshheading:8550787-Male,
pubmed-meshheading:8550787-Molecular Sequence Data,
pubmed-meshheading:8550787-Muscle, Skeletal,
pubmed-meshheading:8550787-Physical Education and Training,
pubmed-meshheading:8550787-RNA, Messenger,
pubmed-meshheading:8550787-Receptors, Somatomedin,
pubmed-meshheading:8550787-Receptors, Somatotropin,
pubmed-meshheading:8550787-Recombinant Proteins,
pubmed-meshheading:8550787-Somatomedins
|
pubmed:year |
1996
|
pubmed:articleTitle |
Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men.
|
pubmed:affiliation |
Musculoskeletal Research Laboratory, Veterans Affairs Medical Center, Palo Alto, California 94304, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Randomized Controlled Trial
|